The aim of this scoping review was to determine the characteristics of studies evaluating fecal microbiota transplantation (FMT), as well as its effects and safety as a therapeutic intervention for people living with human immunodeficiency virus (HIV). We conducted a scoping review following the methodology of the Joanna Briggs Institute. We searched the following databases: PubMed, Web of Science, Scopus, Embase, Cochrane Library, and Medline until September 19, 2021. Studies that used FMT in people living with HIV and explored its effects on the health of these people were included. Two randomized and 2 uncontrolled clinical trials with a total of 55 participants were included. Participants were well-controlled HIV-infected people. Regarding microbiota changes, three studies found significant post-FMT increases in Fusobacterium, Prevotella, α-diversity, Chao index, and/or Shannon index, and/or decreases in Bacteroides. Regarding markers of intestinal damage, one study found a decrease in intestinal fatty acid binding protein post-FMT, and another study found an increase in zonulin. Other outcomes evaluated by the studies were as follows: markers of immune and inflammatory activation, markers of immunocompetence (CD4+, and CD8+ T lymphocytes), and HIV viral load; however, none showed significant changes. Clinical outcomes were not evaluated by these studies. Regarding the safety of FMT, only mild adverse events were appreciated. No serious adverse event was reported. The clinical evidence for FMT in people living with HIV is sparse. FMT appears to have good tolerability and, no serious adverse event has been reported so far. Further clinical trials and evaluation of clinically important biomedical outcomes for FMT in people living with HIV are needed.


Human immunodeficiency virus (HIV) infection causes a chronic inflammatory state, which is characterized by a high turnover and activation of T and B lymphocytes with increased proinflammatory mediators.1 One of the factors contributing to this inflammatory state is the change in the composition of the intestinal microbiota characterized by a decrease in symbiotic bacteria and an increase in pathobiont bacteria.2 In addition, there is a depletion of CD4+ T lymphocytes at the intestinal barrier, with destruction of tight junctions, decreased IgA, dysfunctional macrophages, and death of enterocytes, all of which facilitate the translocation of pathogens3 and microbial products from the permeable intestinal barrier into the circulatory system. As a result, there is production of proinflammatory cytokines such as interleukin (IL)-1b, IL-6, tumor necrosis factor (TNF), interferon (IFN)a, and IFNb.4
Certain interventions, such as dietary modification with the use of prebiotics that would restore intestinal bacteria, inhibition of microbial enzymes that exacerbate intestinal inflammation, targeted elimination of microbiota flora through phages, and fecal microbiota transplantation (FMT), have been proposed as potential therapeutic measures to reverse these alterations.5 FMT is the transfer of stool from healthy donors with the aim of normalizing the composition and function of intestinal microbiota.6 Good tolerability and safety have been reported with this strategy, as well as an increase in microbial diversity and improvement of intestinal inflammatory markers in people living with HIV.7 However, great variability has been identified in the outcomes evaluated by the studies, so a scoping review approach was chosen to identify the available evidence on this topic.8
This scoping review aims to determine the characteristics of studies evaluating FMT, as well as its effects and safety as a therapeutic intervention for people living with HIV.


We performed a scoping review following the guidelines of the Preferred Reporting Items for Systematic and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) of 20209 and the methodology described by the Joanna Briggs Institute.10 The study protocol was registered on the Figshare platform (FMT for people with HIV: a scoping review protocol).

Eligibility criteria

We have included clinical trials and observational studies that reported health-related outcomes described post-FMT in people living with HIV. Case reports, editorials, commentaries, reviews, and studies not available in full text were excluded.

Literature search

The following databases were searched for articles: (1) PubMed, (2) Web of Science/Core collection, (3) Scopus, (4) Embase, (5) Cochrane Library, and (6) Web of Science/MEDLINE. The search was conducted on September 19, 2021. There was no restriction regarding language or date of publication. Search terms were grouped into two categories: HIV/AIDS and fecal transplantation. The full search can be found in Supplementary Table S1.

Study selection

Duplicate items were manually removed with EndNote software.11 Subsequently, the studies were imported into the Rayyan software.12 Two authors (B.C.-C. and I.P.-L.) independently reviewed the titles and abstracts of the results to identify potentially relevant studies for inclusion. These studies were full-text reviewed independently by two different authors (K.F.-L. and A.G.-U.). Any disagreement in selection was discussed with another author (D.R.S.-M.) and resolved by consensus. In addition, the reference list of all included studies was reviewed to complement the search.

Data charting

An extraction sheet was designed in Microsoft Excel and the data of interest were obtained independently by the authors (D.F.-G. and J.F.-M.). Discrepancies were resolved with two different authors (D.R.S.-M. and S.M.-R.). The following variables were extracted from each study: first author, year of publication, country, study design, population characteristics (age, sex, and number of participants), follow-up time, HIV status of the patients, donor features, details of FMT, outcomes assessed by the studies, and adverse events. Regarding outcomes, we only included those that gave some statistical measure (e.g., p value) to know whether the change was significant or not.

Synthesis of results

A descriptive synthesis of the results of included studies was performed. We made tables and figures to summarize the characteristics, outcomes, and adverse events reported by the studies.


Study characteristics

The systematic search identified 274 studies through database and registers after removing duplicates. We identified 193 studies from references of included articles. After screening, we obtained 15 studies (12 from database and registers, and 3 from references), which were reviewed in full text to assess their eligibility. Finally, four studies were included in the review (Fig. 1). The reasons for the exclusion of full-text reviewed articles are detailed in Supplementary Table S2. The studies were clinical trials, two of which were randomized13,14 and two uncontrolled.15,16 The follow-up time for these studies was at least 24 weeks. There were 55 participants in total, more than 85% were men. Their age ranged from 28 to 72 years. The participants were well-controlled HIV-infected adult people on highly active antiretroviral therapy (HAART).13–16
FIG. 1. Flow diagram summarizing the process of literature search and selection.
One study included patients during at least 48 weeks on stable HAART13 and another during at least 24 weeks.15 Almost all participants continued with HAART during follow-up. Two studies included only men who have sex with men (MSM)15,16 and another included a high proportion of MSM.13 In Serrano-Villar et al.'s 13 study, six participants received antibiotics in the 14 weeks before the intervention; and in SahBandar et al.'s study,16 nine participants received antibiotics in the 5 days before the intervention. Two studies administered FMT orally with multiple doses13,15 and two studies administered FMT by colonoscopy.14,16 Donors were healthy adults with high Bacteroides concentrations (Table 1).
Table 1. Characteristics of Included Studies Evaluating Fecal Microbiota Transplantation in People Living with Human Immunodeficiency Virus (n = 4)
Author (year)CountryDesignSample size% Male sexAge ± SD, yearsFollow-up, weeksHIV statusDonor detailsFecal microbiota transplantation details
Serrano-Villar et al. (2021)13SpainRandomized clinical trial2989.747.0 ± 11.10, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, and 4869% MSM on stable triple ART with plasma HIV RNA <37 copies/mL during at least 48 weeks and a CD4/CD8 ratio <1Upper quartile of abundance and butyrate concentrations of the fecal Bacteroides and Faecalibacterium genera, and in the lower quartile of Prevotella abundanceOral administration of capsules vs. placebo. Induction dose with 10 capsules (single dose). And maintenance dose weekly with 5 capsules for 7 weeks.
Utay et al. (2020)15United StatesUncontrolled clinical trial610039.0 ± 22.90, 6, and 26MSM, HIV positive, on continuous triple ART for ≥24 weeks, with CD4+ T cell count >350 cells/mm3, HIV RNA levels <20 copies/mL for ≥12 weeks, and absolute neutrophil count ≥1,000 cells/mm3Healthy men 56 to 68 years old with BMI <30 kg/m2 and no personal or family history of disease suspected to be transmitted by the microbiome150 g of stool (lyophilized to ∼2.25 g) from 1 of 3 donors, weekly for 6 weeks. Participants fasted, except for water, for 8 h before the intervention. They took the product under supervision and were monitored for 1.5 h after ingestion.
SahBandar et al. (2020)16United StatesUncontrolled clinical trial1210054.8 ± 12.9−4, −2, 0, 1, 2, 4, 8, and 24MSM, HIV positive, on stable combination ART, with viral load undetectable, CD4 count >250 cell/mm3Low in Proteobacteria and high in Bacteroidetes.Participants underwent a standard bowel purge the day before the intervention and the 250 mL fecal suspension was administered through colonoscopy into the ileum, cecum, and ascending colon.
Vujkovic-Cvijin et al. (2017)14United StatesRandomized clinical trial887.556.3 ± 13.7−4, −2, 0, 1, 2, 4, 8, and 24Participants on continuous ART with full viral load suppression. CD4 > 250 cell/mm3Low in Proteobacteria and high in Bacteroidetes.Participants underwent a standard bowel purge the day before the intervention and the 250 mL fecal suspension was administered through colonoscopy into the ileum, cecum, and ascending colon.
ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; MSM, men who have sex with men; SD, standard deviation.

Clinical outcomes and markers of immunocompetence

None of the studies evaluated clinical outcomes. Regarding immunocompetence markers, three studies evaluated CD4+ and CD8+ T lymphocytes, and CD4+/CD8+ ratio.13–15 Only Utay et al. measured HIV RNA viral load.15 No significant change in these outcomes was found.

Inflammatory and immune activation markers

In terms of macrophage activation markers, sCD14 level and sCD163 were evaluated by three and two studies, respectively.13,15 Two studies analyzed IFN-γ levels.15,16 Other assessed markers were as follows: IL levels, TNF-related weak inducer of apoptosis (TWEAK), matrix metallopeptidase 1, plasma kynurenine to tryptophan ratio, D-dimer, IFN-γ-induced protein 10, and soluble tumor necrosis factor receptor type II.15 None of the studies found significant changes in markers of inflammation and immune activation.

Microbiota modification

The studies evaluated the microbiota by 16s rRNA sequencing, except for Utay et al.'s study, which did not provide details. The following bacteria were evaluated: Fusobacterium, Faecalibacterium, Rikenellaceae, Prevotella, Erysipelotrichaceae, and Bacteroides. One study found a significant increase in the population of Fusobacterium,15 and another found a significant increase in the population of Prevotella and a significant decrease in Bacteroides.14 In addition, the α-diversity was evaluated by three studies,13–15 finding a significant increase in only one of them.13 Furthermore, Serrano-Villar et al. found a significant increase in Chao index and Shannon index.13

Bacterial translocation and gut damage markers

The selected studies evaluated markers of intestinal damage such as intestinal fatty acid binding protein (IFABP),13,15 zonulin,13,15 and flagellin.15 Serrano-Villar et al. found a significant decrease in IFABP levels,13 and Utay et al. found a significant increase in zonulin levels.15 Regarding markers of bacterial translocation such as lipopolysaccharide binding protein and lipoteichoic acid, no significant change was found.15 All outcomes are detailed in Figure 2.
FIG. 2. Outcomes evaluated in studies evaluating fecal microbiota transplantation in people with HIV (n = 4). HIV, human immunodeficiency virus.

Adverse events

Adverse events reported in the groups receiving FMT were nausea, abdominal pain, bloating, flatulence, and diarrhea. SahBandar et al.'s study did not report adverse events. There was no serious adverse event developed by the participants in any of the studies (Table 2).
Table 2. Adverse Event Frequency of Fecal Microbiota Transplantation in People with Human Immunodeficiency Virus (n = 4)
Author (year)GroupNauseaAbdominal painAbdominal distensionFlatulenceDiarrheaSerious adverse events
Serrano-Villar et al. (2021)13Intervention group (n = 14)0035.7%35.7%35.7%0
Control group (n = 15)0006.7%00
Utay et al. (2020)15Intervention group (n = 6)16.7%16.7%16.7%000
SahBandar et al. (2020)16Intervention group (n = 12)Not reported
Vujkovic-Cvijin et al. (2017)14Intervention group (n = 6)000000
Control group (n = 2)000000


Main results

In this scoping review, we included four clinical trials (two randomized and two uncontrolled) that evaluated FMT in people living with HIV. The outcomes assessed by these studies were markers of immunocompetence, HIV viral load, markers of inflammatory and immune activation, microbiota modification and bacterial translocation, and markers of intestinal damage. Some studies reported significant changes in the composition of intestinal microbiota and markers of intestinal damage. However, no study evaluated clinical outcomes. Regarding safety and tolerability, there was no serious adverse event, but mild side effects such as bloating and mild abdominal pain, flatulence, nausea, and diarrhea were reported.

Characteristics of the studies

The four trials included people living with HIV with different clinical and immunological characteristics, and three studies included a high proportion of MSM.13,15,16 The importance of considering this characteristic in people living with HIV laid in the fact that sexual preferences could generate alterations in the microbiota, increasing the presence of Prevotella and favoring alpha and beta diversity.17–19
Regarding the method of administration of FMT, we observed that two studies used the oral route (ingestion of the product or capsules) and two used colonoscopy. These routes have been previously considered in previous studies that evaluated the effect of FMT on Clostridium difficile infection, with a higher cure rate observed in those who used colonoscopy, followed by capsule and enema, with the lowest cure rates observed with nasogastric tube administration20; this could suggest that passage through the upper digestive tract could interfere with the effect of FMT.
Similarly, administration of FMT as an intervention to seek clinical remission of ulcerative colitis was more effective when colonoscopy was used compared to the oral route.21 The role of bowel purging before colonoscopy has not been evaluated; however, there would be no theoretical support for thinking that it could modify the microbiome of patients with HIV.14–16
On the other hand, the volume and frequency of FMT administration were not equal for studies that evaluated the effect of oral FMT, whereas for studies using colonoscopy, the volume and segments of the colon where it was administered were standard. In previous studies on the effectiveness of FMT for the cure of C. difficile infection, it has been observed that dose heterogeneity does not show linearity or association with a higher cure rate.22 Similarly, Wang et al.23 evidenced that an induction dose may not contribute significantly to treatment success. On the other hand, a systematic review of 37 studies evaluating FMT in patients with recurrent C. difficile infection found that repeated doses of FMT were associated with greater clinical success.22
In addition, a systematic review of four interventional studies, which evaluated the effect of FMT as salvage therapy in patients with ulcerative colitis, mentioned that the treatment provided clinical remission after 8 weeks of multiple administrations of FMT.24
In people living with HIV, there is even greater uncertainty about the dosing, route of administration, and follow-up time of TMF. Clearly, more studies are needed to determine these aspects. With respect to uncontrolled studies, it is not possible to conclude with certainty that changes in outcomes were due to FMT, given the absence of a control group. In addition, the randomized control trials and uncontrolled studies had small sample sizes.

Changes in immune response

It has been proposed that the FMT or modification of the microbiome is beneficial for the immune system, influencing the response of T cells and reversal of dysbiosis in people with HIV and gastrointestinal tract diseases.25–29 In this review, we found that FMT did not modify CD4+, CD8+ levels, CD4+/CD8+ ratio, and inflammatory markers.13–15 It is possible that due to the small sample size of the studies, no benefit was found. Studies with a larger number of participants and with a longer follow-up time are needed to evaluate these important outcomes.

Changes in the microbiota

Studies have demonstrated that the microbiota of people living with HIV suffers an alteration in its composition, which causes dysbiosis,30 leading to an increase in bacteria that produce proinflammatory substances (Erysipelotrichaceae, Enterobacteriaceae, Fusobacteria, and Prevotella) and a decrease in anti-inflammatory bacteria (Bacteroides and Rikenellaceae). These events trigger the dysregulation of different subsets of T cells, generating inflammation and prolonged damage to the organism.5,31–33 Therefore, controlling the colonization of bacterial colonies in the microbiota may be used as a therapeutic strategy aiming to restore the homeostasis in people living with HIV.
In this review, the study conducted by SahBandar et al. demonstrated the persistence of Fusobacterium post-FMT. Utay et al. found an increase in intestinal Fusobacterium colonization, and Vujkovic-Cvijin et al. observed an increase in Prevotella and a decrease in Bacteroides during follow-up, these changes being statistically significant. This paradoxical finding suggests that FMT may contribute to the increased dysregulation between proinflammatory and anti-inflammatory bacteria.
On the other hand, Utay et al.'s study15 showed an increase in the variety and abundance of microorganisms in the microbiota (alpha diversity) during the first 6 weeks among people with low diversity. Meanwhile, Serrano-Villar et al.'s13 study revealed an increase in alpha diversity,34 as well as in their richness and uniformity (Shannon index). They also noted an elevation in the richness of microorganisms that differ between each patient (Chao index).35
Regarding the composition of the donor's microbiota, Serrano-Villar et al.'s study showed that there was a more pronounced effect on the alpha diversity of the participants who were assigned to a donor whose main characteristic was a greater abundance of the family Ruminococcaceae compared to other donors. However, this could not be conclusive because three out of five recipients of the donor had received antibiotics before the FMT intervention. This could have influenced the response after the intervention. Further studies should include donors with a microbiome with a predominance of microorganisms with anti-inflammatory effects.
Although the microbiota is not an absolute determinant associated with health problems, it is a mediating factor that could influence patient health, since a functional microbiota could reduce persistent and chronic inflammation during HIV disease.36,37 Previous studies have shown that, in response to deregulation in the composition of the microbiota, it could generate health problems due to the production of immunomodulatory substances, which could be involved in inflammatory bowel diseases and colorectal cancer, among others.38 On the other hand, it could generate less immune activation, being more prone to infections by opportunistic pathogen.37,39

Markers of intestinal damage

People living with HIV have local inflammatory response, which is measured indirectly by biomarkers intestinal damage (e.g., IFABP).40–42 In this review, we found inconsistent results regarding whether FMT increases or decreases this intestinal damage, as measured by biomarkers. The study conducted by Serrano-Villar et al. found a decrease in IFABP post-FMT, indicating a decrease in intestinal damage, while Utay et al. observed an elevated concentration of zonulin, a marker of intestinal permeability, which would reflect a turnover of healthy intestinal epithelial.43 An increase in the levels of zonulin has been associated with lower mortality in people living with HIV.40

Adverse events

Regarding tolerability and adverse effects of FMT, studies reported mild adverse events after both oral and colonoscopy procedures. In this regard, 7% of patients undergoing a colonoscopy could develop complications highlighting the bleeding and perforation.44 This could imply a higher risk of complications compared to the oral route. Similarly, in a meta-analysis of adverse events of FMT, 4 out of 10 patients who received FMT for the management of different pathologies most frequently experienced bloating, abdominal pain, nausea, vomiting, and diarrhea, with C. difficile infection being the most serious adverse effect of FMT in immunocompetent individuals. This latter event was very infrequent.45 Therefore, intervention in immunosuppressed patients should be performed under continuous supervision and monitoring.

Limitations of the studies

The main limitation of the included studies was the small sample size (with a minimum of 6 and a maximum of 29 participants included). Furthermore, they were heterogeneous in terms of characteristics of participants and donors, intervention, follow-up time, and parameters to assess the efficacy of FMT. Another important limitation was that two studies had no comparator group. Finally, no study evaluated clinical outcomes.

Implications and recommendations

From this scoping review, we provide a general approach to be considered before developing future studies about FMT in people living with HIV. We recommend that the research conducted to evaluate FMT incorporates standardization of the intervention according to the methodologies used in the included studies (sample collection from specific donors, sample meeting microbiological criteria, and administration under protocol if colonoscopy is used). In addition, adequate follow-up should be considered to evaluate the results of the intervention with the following parameters: immune markers (CD4 level, CD8, and CD4/CD8 ratio), HIV viral load, inflammatory markers, immune activation markers, and changes in the microbiota, as well as clinical outcomes (opportunistic infections, mortality, etc.).

Limitations and strengths

Our scoping review has some limitations that should be taken into account. The primary evidence was sparse. We did not formally assess the methodological quality of studies that evaluated FMT. In addition, by including only published studies, there is the possibility of incurring in publication bias. Despite these limitations, this is the first scoping review that provides an overview of the literature in this area. The review was based on the methodology recommended by the JBI and PRISMA guidelines.9,10 Finally, we believe that our results may contribute to build up the scientific evidence about FMT in people living with HIV. The methods of the review and search strategies may serve to guide the development of a protocol for future systematic reviews on this topic.


Sparse evidence is available on the benefits and potential risks of FMT in people living with HIV. With the available data, we cannot recommend its use in clinical practice. More clinical trials are needed to assess the efficacy and safety of this intervention.

Supplementary Material

File (supp_tables1.docx)
File (supp_tables2.docx)


1. Hazenberg MD, Stuart JW, Otto SA, et al.: T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000;95:249–255.
2. Dillon SM, Frank DN, Wilson CC: The gut microbiome and HIV-1 pathogenesis: A two-way street. AIDS 2016;30:2737–2751.
3. Allers K, Fehr M, Conrad K, et al.: Macrophages accumulate in the gut mucosa of untreated HIV-infected patients. J Infect Dis 2014;209:739–748.
4. Sandler NG, Douek DC: Microbial translocation in HIV infection: Causes, consequences and treatment opportunities. Nat Rev Microbiol 2012;10:655–666.
5. Vujkovic-Cvijin I, Somsouk M: HIV and the gut microbiota: Composition, consequences, and avenues for amelioration. Curr HIV/AIDS Rep 2019;16:204–213.
6. Vindigni SM, Surawicz CM: Fecal microbiota transplantation. Gastroenterol Clin North Am 2017;46:171–185.
7. Hensley-McBain T, Zevin AS, Manuzak J, et al.: Effects of fecal microbial transplantation on microbiome and immunity in Simian immunodeficiency virus-infected Macaques. J Virol 2016;90:4981–4989.
8. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E: Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol 2018;18:143.
9. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;29:n71.
10. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB: Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc 2015;13:141–146.
11. Bramer WM: Reference checking for systematic reviews using Endnote. J Med Libr Assoc 2018;106:542–546.
12. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A: Rayyan—A web and mobile app for systematic reviews. Syst Rev 2016;5:210.
13. Serrano-Villar S, Talavera-Rodríguez A, Gosalbes MJ, et al.: Fecal microbiota transplantation in HIV: A pilot placebo-controlled study. Nat Commun 2021;12:1139.
14. Vujkovic-Cvijin I, Rutishauser RL, Pao M, et al.: Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes 2017;8:440–450.
15. Utay NS, Monczor AN, Somasunderam A, et al.: Evaluation of six weekly oral fecal microbiota transplants in people with HIV. Pathog Immun 2020;5:364–381.
16. SahBandar IN, Chew GM, Corley MJ, et al.: Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade. AIDS 2020;34:1451–1460.
17. Noguera-Julian M, Rocafort M, Guillén Y, et al.: Gut microbiota linked to sexual preference and HIV infection. EBioMedicine 2016;5:135–146.
18. Kelley CF, Kraft CS, de Man TJ, et al.: The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: Implications for HIV transmission and prevention. Mucosal Immunol 2017;10:996–1007.
19. Jabłonowska E, Strzelczyk J, Piekarska A, Wójcik-Cichy K: Gut microbiota diversity in HIV-infected patients on successful antiretroviral treatment is linked to sexual preferences but not CD4 nadir. Arch Immunol Ther Exp 2021;69:14.
20. Ramai D, Zakhia K, Fields PJ, et al.: Fecal microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent Clostridium difficile infection: A systematic review and meta-analysis. Dig Dis Sci 2021;66:369–380.
21. Moayyedi P, Surette MG, Kim PT, et al.: Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102–109.e6.
22. Quraishi MN, Widlak M, Bhala N, et al.: Systematic review with meta-analysis: The efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017;46:479–493.
23. Wang J-W, Kuo C-H, Kuo F-C, et al.: Fecal microbiota transplantation: Review and update. J Formos Med Assoc 2019;118:S23–S31.
24. Imdad A, Nicholson MR, Tanner-Smith EE, et al.: Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2018;11:CD012774.
25. Mullish BH, Quraishi MN, Segal JP, et al.: The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2018;67:1920–1941.
26. Cammarota G, Ianiro G, Tilg H, et al.: European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66:569–580.
27. Kang Y, Cai Y: Altered gut microbiota in HIV infection: Future perspective of fecal microbiota transplantation therapy. AIDS Res Hum Retroviruses 2019;35:229–235.
28. Zilberman-Schapira G, Zmora N, Itav S, Bashiardes S, Elinav H, Elinav E: The gut microbiome in human immunodeficiency virus infection. BMC Med 2016;14:83.
29. Gong D, Gong X, Wang L, Yu X, Dong Q: Involvement of reduced microbial diversity in inflammatory bowel disease. Gastroenterol Res Pract 2016;2016:6951091.
30. Neff CP, Krueger O, Xiong K, et al.: Fecal microbiota composition drives immune activation in HIV-infected individuals. EBioMedicine 2018;30:192–202.
31. Serrano-Villar S, Ferrer M, Gosalbes MJ, Moreno S: How can the gut microbiota affect immune recovery in HIV-infected individuals? Future Microbiol 2017;12:195–199.
32. Dubourg G, Surenaud M, Lévy Y, Hüe S, Raoult D. Microbiome of HIV-infected people. Microbial Pathogenesis. 2017;106:85–93.
33. Klase Z, Ortiz A, Deleage C, Mudd JC, Quiñones M, Schwartzman E, et al.: Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunology. 2015;8:1009–1020.
34. Wagner BD, Grunwald GK, Zerbe GO, Mikulich-Gilbertson SK, Robertson CE, Zemanick ET, et al.: On the use of diversity measures in longitudinal sequencing studies of microbial communities. Frontiers in Microbiology. 2018;9:1037.
35. Hill TCJ, Walsh KA, Harris JA, Moffett BF. Using ecological diversity measures with bacterial communities. FEMS Microbiology Ecology. 20031;43:1–11.
36. Ling Z, Jin C, Xie T, Cheng Y, Li L, Wu N: Alterations in the fecal microbiota of patients with HIV-1 infection: An observational study in a Chinese population. Sci Rep 2016;6:30673.
37. Vázquez-Castellanos JF, Serrano-Villar S, Latorre A, et al.: Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol 2015;8:760–772.
38. Cho I, Blaser MJ: The human microbiome: At the interface of health and disease. Nat Rev Genet 2012;13:260–270.
39. Ducarmon QR, Zwittink RD, Hornung BVH, van Schaik W, Young VB, Kuijper EJ: Gut microbiota and colonization resistance against bacterial enteric infection. Microbiol Mol Biol Rev 2019;83:e00007-19.
40. Hunt PW, Sinclair E, Rodriguez B, et al.: Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014;210:1228–1238.
41. Utay NS, Somasunderam A, Hinkle JE, et al.: Serum bovine immunoglobulins improve inflammation and gut barrier function in persons with HIV and enteropathy on suppressive ART. Pathog Immun 2019;4:124–146.
42. Koay WLA, Lindsey JC, Uprety P, et al.: Intestinal integrity biomarkers in early antiretroviral-treated perinatally HIV-1–infected infants. J Infect Dis 2018;218:1085–1089.
43. Fasano A: Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer. Physiol Rev 2011;91:151–175.
44. Kim HI, Yoon JY, Kwak MS, Cha JM: Gastrointestinal and nongastrointestinal complications of esophagogastroduodenoscopy and colonoscopy in the real world: A nationwide standard cohort using the common data model database. Gut Liver 2021;15:569–578.
45. Michailidis L: Adverse events of fecal microbiota transplantation: A metaanalysis of high-quality studies. Ann Gastroenterol 2021;34:802–814.

Information & Authors


Published In

cover image AIDS Research and Human Retroviruses
AIDS Research and Human Retroviruses
Volume 38Issue Number 9September 2022
Pages: 700 - 708
PubMed: 35451337


Published online: 12 September 2022
Published in print: September 2022
Published ahead of print: 24 May 2022
Published ahead of production: 22 April 2022


Request permissions for this article.




Brenda Caira-Chuquineyra
Peruvian Epidemiological Research Group, Unit for the Generation and Synthesis of Health Evidence, San Ignacio de Loyola University, Lima, Peru.
Faculty of Medicine, National University of San Agustín, Arequipa, Peru.
Daniel Fernandez-Guzman
Peruvian Epidemiological Research Group, Unit for the Generation and Synthesis of Health Evidence, San Ignacio de Loyola University, Lima, Peru.
Professional School of Human Medicine, National University of San Antonio Abad del Cusco, Cusco, Peru.
Clinical and Epidemiological Research Unit, School of Medicine, Peruvian Union University, Lima, Peru.
Jared Fernandez-Morales
Clinical and Epidemiological Research Unit, School of Medicine, Peruvian Union University, Lima, Peru.
Kevin Flores-Lovon
Faculty of Medicine, National University of San Agustín, Arequipa, Peru.
Sebastian A. Medina-Ramírez
Clinical and Epidemiological Research Unit, School of Medicine, Peruvian Union University, Lima, Peru.
Antony G. Gonzales-Uribe
Clinical and Epidemiological Research Unit, School of Medicine, Peruvian Union University, Lima, Peru.
Isabel P. Pelayo-Luis
Clinical and Epidemiological Research Unit, School of Medicine, Peruvian Union University, Lima, Peru.
Jose A. Gonzales-Zamora
Division of Infectious Diseases, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Peruvian American Medical Society, Albuquerque, New Mexico, USA.
Jorge Huaringa-Marcelo
Faculty of Human Medicine, Scientific University of the South, Lima, Peru.
Archbishop Loayza National Hospital, Lima, Peru.


Address correspondence to: David R. Soriano-Moreno, Clinical and Epidemiological Research Unit, School of Medicine, Peruvian Union University, Carretera Central Km 19.5 Ñaña, Chosica, Lima 15476, Peru [email protected]

Authors' Contributions

B.C.-C. and D.F.-G. conceived the study. All the authors wrote the article. D.R.S.-M., J.A.G.-Z., and J.H.-M. critically reviewed the article. All authors contributed to and approved the final version.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

No funding was received for this article.

Metrics & Citations



Export citation

Select the format you want to export the citations of this publication.

View Options

View options


View PDF/ePub

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.







Copy the content Link

Share on social media

Back to Top